#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
proLékaře.cz / Topic

Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation

We recommend úhradové podmínky

Current Reimbursement Conditions for the Dual Inhibitor IL-4/IL-13 Dupilumab

4. 3. 2024 Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation

The biologic dupilumab is approved for the treatment of several diseases with type 2 inflammation. What is the current reimbursement situation in key indications? We summarize in the following brief overview.

Salavec FOTO

Doc. Miloslav Salavec: We Still Encounter Delayed Initiation of Biological Treatment in AD and Many Other Diagnoses

Not all patients with atopic dermatitis (AD) who are indicated for biological treatment with…
4. 12. 2023 Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation
dívka s atopickou dermatitidou na rukou

Laboratory Safety of Dupilumab Treatment in Children with Atopic Dermatitis Aged 6 Months to 6 Years

Previous clinical studies in children aged 6–12 years with moderate-to-severe atopic dermatitis…
1. 9. 2023 Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation
Articles on this topic
prim. Miroslav Nečas

What is new in the treatment of atopic dermatitis and how are comorbidities affecting it?

Allergic rhinitis, conjunctivitis, bronchial asthma, or autoimmune diseases like alopecia,…
26. 6. 2023 Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation
atopická dermatitida na ruce

Meta-analysis of the efficacy and safety of dupilumab in the treatment of atopic dermatitis in children and adults

Moderate to severe atopic dermatitis (AD) is accompanied by strong inflammatory processes that…
13. 6. 2023 Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation
plíce 3D model

Infographic and Commentary from Practice: Reasons and Pathways for Patients to Biological Treatment of Asthma

For asthma patients with the most severe forms of the disease to access targeted biological…
28. 4. 2023 Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation
leky na astma

Efficacy and Safety of Dupilumab in the Treatment of Severe Asthma Insufficiently Controlled by Standard Therapy –⁠ Current Clinical Practice Data

If severe bronchial asthma with type 2 inflammation is insufficiently controlled by combined…
16. 3. 2023 Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation
mladá dívka s AD

Targeted Treatment of Children and Adolescents with Severe AD –⁠ Case Studies

The results of therapy with dupilumab in children and adolescents with severe forms of atopic dermatitis...
2. 3. 2023 Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation
těžká AD u dospělého

Long-term Safety of Dupilumab in Adult Patients with Moderate to Severe Atopic Dermatitis

Moderate to severe atopic dermatitis (AD) often requires systemic therapy. The long-term…
24. 1. 2023 Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation
nosní polypy orl

Comparison of Biologics in the Treatment of Chronic Rhinosinusitis with Nasal Polyps

The authors of a meta-analysis of nine randomized controlled trials comparing dupilumab,…
7. 9. 2022 Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation
atopická dermatitida detail kůže

Dupilumab Improves Skin and Systemic Symptoms of Atopic Dermatitis

A clinical study conducted in the USA and Canada demonstrated the efficacy of dupilumab in…
20. 6. 2022 Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation
prim Ondrejka

Prim. MUDr. Gustáv Ondrejka: Biological treatment of asthma eliminates the need for systemic corticotherapy

Despite advances in the therapy of bronchial asthma, a portion of patients still do not…
18. 4. 2022 Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation
žena těžké astma

Treatment with Dupilumab in Severe Corticosteroid-Dependent Bronchial Asthma –⁠ A Case Study

We present the case of a 36-year-old woman with severe corticosteroid-dependent asthma with…
4. 4. 2022 Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation
modřina kotník

Is Dupilumab Effective in AD Therapy for Patients for Whom Cyclosporine A Fails or Cannot Be Given?

Severe forms of atopic dermatitis (AD) may require systemic therapy. However, the…
3. 3. 2022 Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation
kůže atopic dítě dermatitida ekzém

Dupilumab Now Covered for Atopic Dermatitis in Children Older Than 6 Years

Dupilumab is now fully covered by public health insurance for pediatric patients from 6 years…
22. 1. 2022 Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation
atopic_svědění_adolescent

Efficacy and Safety of Dupilumab in the Treatment of Atopic Dermatitis in Adolescents

In the pediatric population, atopic dermatitis (AD) has a relatively high prevalence, but…
1. 11. 2021 Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation
:IMPORT-RN:

Quick Relief from Severe AD Symptoms –⁠ Dupilumab for Children Aged 6 Years and Older

Children aged 6-12 with severe atopic dermatitis (AD) have very limited treatment options. The…
1. 11. 2021 Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation
PL_astma_inhalator_zena_kasel

Alleviation of Asthma and Chronic Sinusitis Symptoms in Patients with Atopic Dermatitis Thanks to Dupilumab

An analysis of results in adult patients with moderate to severe atopic dermatitis, who also…
12. 8. 2021 Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation
1 2
Subscribe
E-courses on this topic

Course detail
Most read on this topic
Journal on this topic
Issue 7–8
Journal of Czech Physicians
Issue 2
Czech Rheumatology
Related topic
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#